EMA Authorised: Vectibix (panitumumab) — Amgen Europe B.V.

View source ↗

Summary

EMA authorised Vectibix (panitumumab) for colorectal neoplasms, with Amgen Europe B.V. as the marketing authorization holder; decision date 13/03/2025. This con…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• Vectibix (panitumumab)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms. MAH: Amgen Europe B.V.. Decision date: 13/03/2025